Patents by Inventor Richard P. Batycky
Richard P. Batycky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230053976Abstract: The present invention provides methods for treating OFF episodes in a Parkinson's Disease patient comprising administering levodopa to the pulmonary system of a patient wherein after administration, the patient's Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 score is improved by, for example, at least about 5 points as compared to placebo control and/or as compared to the patient's UDPRS Part 3 score prior to administration. The invention also provides methods of reducing mean daily OFF time in a Parkinson's patient.Type: ApplicationFiled: January 26, 2022Publication date: February 23, 2023Inventors: Richard P. Batycky, Martin Freed, Michael M. Lipp
-
Publication number: 20170354602Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.Type: ApplicationFiled: January 26, 2017Publication date: December 14, 2017Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
-
Publication number: 20170296498Abstract: The present invention provides methods for treating OFF episodes in a Parkinson's Disease patient comprising administering levodopa to the pulmonary system of a patient wherein after administration, the patient's Unified Parkinson's Disease Rating Scale (UP-DRS) Part 3 score is improved by, for example, at least about 5 points as compared to placebo control and/or as compared to the patient's UDPRS Part 3 score prior to administration. The invention also provides methods of reducing mean daily OFF time in a Parkinson's patient.Type: ApplicationFiled: April 21, 2014Publication date: October 19, 2017Inventors: Richard P. Batycky, Martin Freed, Michael M. Lipp
-
Publication number: 20170119699Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.Type: ApplicationFiled: December 23, 2016Publication date: May 4, 2017Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
-
Patent number: 9539211Abstract: The invention provides pharmaceutical compositions for pulmonary delivery comprising particles containing a pharmaceutical agent and having a geometric size of greater than about 5 ?m and a tap density of less than about 0.075 g/cm3. The invention also provides methods for delivering the pharmaceutical compositions of the invention to the respiratory tract of a patient.Type: GrantFiled: May 8, 2015Date of Patent: January 10, 2017Assignee: Civitas Therapeutics, Inc.Inventors: Michael M. Lipp, Richard P. Batycky
-
Publication number: 20160287517Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.Type: ApplicationFiled: April 7, 2016Publication date: October 6, 2016Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
-
Patent number: 9393210Abstract: The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.Type: GrantFiled: December 18, 2014Date of Patent: July 19, 2016Assignee: Civitas Therapeutics, Inc.Inventors: Kevin D. Kee, Ernest D. Penachio, Abhijit Kamerkar, Michael M. Lipp, Richard P. Batycky
-
Patent number: 9333174Abstract: Particles having a tap density of less than 0.4 g/cm3 include a hydrophobic amino acid or salt thereof and a therapeutic, prophylactic or diagnostic agent or any combination thereof. Preferred particles include a phospholipid, have a median geometric diameter between about 5 and about 30 microns and an aerodynamic diameter between about 1 and about 5 microns. The particles can be formed by spray-drying and are useful for delivery to the pulmonary system.Type: GrantFiled: August 17, 2012Date of Patent: May 10, 2016Assignee: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Michael M. Lipp, Ralph W. Niven
-
Patent number: 9295661Abstract: The present invention provides methods of reducing the inter-patient variability of levodopa plasma concentrations in a population of Parkinson's disease patients. The methods of the invention comprise pulmonary administration of levodopa at therapeutically effective concentrations such that the inter-patient variability of levodopa plasma concentrations at time periods ranging from about 10 minutes post inhalation to about 60 minutes or more post inhalation have less than a 50% coefficient variation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a side effect of L-Dopa therapy.Type: GrantFiled: April 21, 2015Date of Patent: March 29, 2016Assignee: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Martin Freed
-
Publication number: 20160015663Abstract: The present invention provides methods of reducing the inter-patient variability of levodopa plasma concentrations in a population of Parkinson's disease patients. The methods of the invention comprise pulmonary administration of levodopa at therapeutically effective concentrations such that the inter-patient variability of levodopa plasma concentrations at time periods ranging from about 10 minutes post inhalation to about 60 minutes or more post inhalation have less than a 50% coefficient variation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a side effect of L-Dopa therapy.Type: ApplicationFiled: April 21, 2015Publication date: January 21, 2016Inventors: Richard P. Batycky, Martin Freed
-
Publication number: 20150342885Abstract: The invention provides pharmaceutical compositions for pulmonary delivery comprising particles containing a pharmaceutical agent and having a geometric size of greater than about 5 ?m and a tap density of less than about 0.075 g/cm3. The invention also provides methods for delivering the pharmaceutical compositions of the invention to the respiratory tract of a patient.Type: ApplicationFiled: May 8, 2015Publication date: December 3, 2015Inventors: Michael M. Lipp, Richard P. Batycky
-
Publication number: 20150328175Abstract: The present invention provides methods of providing rapid relief of motor fluctuations in a Parkinson's disease patient. The methods of the invention comprise pulmonary administration of levodopa by inhalation at therapeutically effective concentrations such that the patient's plasma levodopa concentration increases by at least about 200 ng/ml within 10 minutes or less post inhalation as compared to the concentration of levodopa in the patient's plasma prior to inhalation of the levodopa and wherein the patient's plasma concentration remains increased by at least about 200 ng/ml for a time period of at least 15 minutes after inhalation. The methods of the invention are particularly useful for treatment of motor fluctuations which arise as a result of poorly controlled levodopa plasma levels in a patient.Type: ApplicationFiled: April 21, 2015Publication date: November 19, 2015Inventors: Richard P. Batycky, Michael M. Lipp, Martin Freed
-
Publication number: 20150320711Abstract: The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.Type: ApplicationFiled: December 18, 2014Publication date: November 12, 2015Inventors: Kevin D. Kee, Ernest D. Penachio, Abhijit Kamerkar, Michael M. Lipp, Richard P. Batycky
-
Publication number: 20150094378Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.Type: ApplicationFiled: May 1, 2014Publication date: April 2, 2015Applicant: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
-
Patent number: 8945612Abstract: The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.Type: GrantFiled: February 6, 2014Date of Patent: February 3, 2015Assignee: Civitas Therapeutics, Inc.Inventors: Kevin D. Kee, Ernest D. Penachio, Abhijit Kamerkar, Michael M. Lipp, Richard P. Batycky
-
Publication number: 20140220119Abstract: The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.Type: ApplicationFiled: February 6, 2014Publication date: August 7, 2014Applicant: Civitas Therapeutics, Inc.Inventors: Kevin D. Kee, Ernest D. Penachio, Abhijit Kamerhar, Michael M. Lipp, Richard P. Batycky
-
Publication number: 20140178476Abstract: A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm3 and deliver at least about 50% of the mass of particles. The particles are capable of carrying agents. The agent is (1) part of the spray-drying pre-mixture and thereby incorporated into the particles, (2) added to separately-prepared particles so that the agent is in chemical association with the particles or (3) blended so that the agent is mixed with, and co-delivered with the particles. Respirable compositions comprising carrier particles having a tap density of less than 0.4 g/cm3 and a composition comprising an agent are also disclosed. Methods of delivering these respirable compositions are also included.Type: ApplicationFiled: December 10, 2013Publication date: June 26, 2014Applicant: Civitas Therapeutics, Inc.Inventors: David A. Edwards, Richard P. Batycky, LIoyd Johnston
-
Patent number: 8747813Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.Type: GrantFiled: March 6, 2013Date of Patent: June 10, 2014Assignee: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
-
Patent number: 8685442Abstract: The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide.Type: GrantFiled: July 18, 2013Date of Patent: April 1, 2014Assignee: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Michael M. Lipp, Abhijit Kamerkar, Ernest D. Penachio, Kevin D. Kee
-
Patent number: 8628754Abstract: A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm3 and deliver at least about 50% of the mass of particles. The particles are capable of carrying agents. The agent is (1) part of the spray-drying pre-mixture and thereby incorporated into the particles, (2) added to separately-prepared particles so that the agent is in chemical association with the particles or (3) blended so that the agent is mixed with, and co-delivered with the particles. Respirable compositions comprising carrier particles having a tap density of less than 0.4 g/cm3 and a composition comprising an agent are also disclosed. Methods of delivering these respirable compositions are also included.Type: GrantFiled: December 22, 2011Date of Patent: January 14, 2014Assignee: Civitas Therapeutics, Inc.Inventors: David A. Edwards, Richard P. Batycky, Lloyd Johnston